New drug takes on T-DXd in breast cancer showdown

NCT ID NCT07416253

Not yet recruiting Disease control Sponsor: Henan Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a new drug, trastuzumab-rezetecan, works as well as the established drug T-DXd in shrinking HER2-positive breast tumors before surgery. About 68 women with early or locally advanced breast cancer will receive one of the two drugs for 8 cycles, then have surgery to see if the cancer has completely disappeared. The study aims to find a potential new treatment option for this type of breast cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trastuzumab-rezetecan (a targeted antibody-drug conjugate) compared to trastuzumab deruxtecan (T-DXd)
What this could lead to: If successful, this could show that trastuzumab-rezetecan is as good as or better than T-DXd at shrinking HER2+ breast tumors before surgery, potentially offering a new treatment option.
What could go wrong: This is a small, early-phase study (68 patients) comparing two similar drugs. It may not show a meaningful difference, and results may not apply to all patients. Side effects from antibody-drug conjugates can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.